The importance of prevention trials in Alzheimer’s disease with Randall Bateman

Video Journal of Biomedicine | Expert Perspective

In this video, Randall Bateman of Washington University, MO, USA provides an overview of primary prevention trials for Alzheimer’s disease, discussing what he sees are the main challenges surrounding such trials and how he anticipates the field progressing over the next 5-10 years.

About the author:

Dr Randall J. Bateman is the Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Dominantly Inherited Alzheimer Network (DIAN), and Director of the DIAN Trials Unit (DIAN-TU). Dr. Bateman’s research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer’s disease. He also treats patients with dementia at the Memory Diagnostic Center of Washington University. For more information about the DIAN and Dr Bateman’s involvement in this network can be found here.

Original publication:

Video originally published on Neuro Central, a digital platform from the Future Science Group that unites all aspects of neurology and neuroscience.